Clinical Trial Update: AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of AMG 706 in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• AMG 706 (motesanib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-01-11